Business description
BRAIN AG is one of Europe’s technological leaders in the field of industrial, or so-called white, biotechnology, the core discipline of the bioeconomy. Using proprietary technology platforms, the company identifies as yet untapped highly performant enzymes, microbial producer organisms or natural substances from complex biological systems in order to transform them into industrially or bioeconomically viable processes. Innovative solutions and products developed from this “toolbox of nature” are already successfully in use in the chemical industry as well as in the cosmetics and foodstuffs industry. BRAIN’s business model is based on two divisions: “BioScience“ and “BioIndustrial”. The “BioScience“ division includes the company’s collaboration business with selected, globally positioned industrial partners, which is usually concluded on an exclusive basis and which has been successfully built and continuously expanded by the company for more than 20 years. The second division, “BioIndustrial”, deals with the development and marketing of BRAIN’s proprietary products and active product components.
Management board & Supervisory board
| CEO |
| Adriaan Moelker |
| Management board |
| Michael Schneiders |
| Supervisory board |
| Dr. Georg Kellinghusen, Dr. Anna C. Eichhorn, Dr. Michael Majerus, Prof. Dr. Bernhard Hauer, Prof. Dr.-Ing. Wiltrud Treffenfeldt, Stephen Catling |
Company data
| Name: |
BRAIN Biotech AG |
| Address: |
Darmstädter Straße 34-36,D-64673 Zwingenberg |
| Phone: |
+49-6251-9331-0 |
| Fax: |
+49-6251-9331-11 |
| E-mail: |
public@brain-biotech.de
|
| Internet: |
www.brain-biotech.de |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
9/30 |
| Free Float: |
44.41% |
| IPO date: |
2/9/2016 |
Investor relations
| Name: |
Michael Schneiders |
| IR phone: |
+49-6251-9331-86 |
| IR Fax: |
- |
| IR e-mail: |
ir@brain-biotech.de
|
